bluebird bio, Inc.
(NASDAQ : BLUE)

( )
BLUE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
-0.24%46.268.1%$690.49m
AMGNAmgen Inc.
-0.23%177.061.3%$495.97m
CELGCelgene Corporation
-0.72%90.871.3%$431.27m
GILDGilead Sciences, Inc.
-0.03%66.920.9%$401.89m
BIIBBiogen Inc.
-0.91%229.441.3%$372.09m
ILMNIllumina, Inc.
0.20%302.903.5%$354.87m
REGNRegeneron Pharmaceuticals, Inc.
0.35%299.422.6%$268.31m
ALXNAlexion Pharmaceuticals, Inc.
0.48%123.412.0%$197.95m
SRPTSarepta Therapeutics, Inc.
0.49%154.0014.7%$197.25m
VRTXVertex Pharmaceuticals Incorporated
0.56%177.141.9%$181.72m
AAgilent Technologies, Inc.
-0.52%69.591.6%$140.09m
EXASExact Sciences Corporation
1.21%116.3424.1%$137.96m
INCYIncyte Corporation
0.44%80.232.5%$110.35m
BLUEBluebird Bio, Inc.
4.33%139.4514.3%$97.87m
BMRNBioMarin Pharmaceutical Inc.
0.12%82.474.3%$84.42m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.